Search
Giloralimab
go.drugbank.com/drugs/DB18862InvestigationalGiloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination … With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
Synonyms: Immunoglobulin g1, anti-(human cd40 antigen) (human-mus musculus monoclonal pr-1614645 .gamma.1-chain), disulfide with human-mus musculus monoclonal pr-1614645 .kappa.-chain, dimerRagifilimab
go.drugbank.com/drugs/DB18853InvestigationalRagifilimab is under investigation in clinical trial NCT04225039 (Anti-gitr/anti-pd1/stereotactic Radiosurgery, in Recurrent Glioblastoma).
Synonyms: Immunoglobulin g1 (de-448-lysine), anti-(human tumor necrosis factor receptor tnfrsf18) (human-mus musculus monoclonal incagn01876.gamma.1-chain), disulfide with human-mus musculus monoclonal incagn01876Ramucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalIn contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. … By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation,
Categories: Vascular Endothelial Growth Factor Receptor 2 AntagonistProducts: CYRAMZA 500 MG/50 ML İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇEREN FLAKON, 1 ADET, CYRAMZA 100MG/10 ML INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇEREN FLAKON, 1 ADETSomatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnIt is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … The actions of somatostatin are mediated via signalling pathways of G protein-coupled somatostatin receptors.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: Synthetic somatostatin-14Technetium Tc-99m mebrofenin
go.drugbank.com/drugs/DB09137ApprovedWithdrawnTechnetium Tc 99m Mebrofenin is a diagnostic radiopharmaceutical composed of diisopropyl-iminodiacetic acid (DISIDA) attached to a technetium-99m ion. … -99m as it decays.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Bis(2-[[2-(3-bromo-2,4,6-trimethylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetate) technetiumAnvatabart opadotin
go.drugbank.com/drugs/DB18290InvestigationalSynonyms: ; conjugated at two engineered sites via a stable, F (pAF) (121), K120 (217) (121- 218), hinge 1-15 (219Testosterone undecanoate
go.drugbank.com/drugs/DB13946ApprovedInvestigationalTestosterone undecanoate is the ester prodrug of [testosterone] and has a mid-chain fatty acid at the carbon 17β position. … [L35970,L8932,L41355] Testosterone is a critical male hormone that is responsible for the normal growth and development of the male sex organs and for the maintenance of secondary sex characteristics
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: NEBIDO 250 MG/ML IM ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET, Nebido 1000 mg/4 ml InjektionslösungLanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[L4538] It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. … Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection.
Categories: Drugs Used in Hereditary AngioedemaProducts: TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADETSecukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque
Categories: Interleukin-17, antagonists & inhibitorsProducts: VERXANT 150 MG/1 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET, VERXANT 150 MG/1 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADETLarotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalLarotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays … It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805]
Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein substratesProducts: VITRAKVI®CÁPSULAS DE 100MG, VITRAKVI 25 MG SERT KAPSÜL, 56 ADET